EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-SA 4.0

Dexmedetomidine Improves Inflammatory Stress and Hemodynamic in Patients Undergoing Open Heart Surgery via Interleukin-13: A Randomized, Double-Blind, Controlled, Clinical Trial

Bassim Mohammed Jabbar Hatemi, Ayesheh Enayati, Somayeh Ghorbani, Fatemeh Tahmasebi, Hadi Abo Aljadayel, Ali Jabbari, Ali Movafegh

Annals of Cardiac Anaesthesia · 2025

DOI: 10.4103/aca.aca_5_25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Cardiac Anaesthesia, 2025. Verfasst von Bassim Mohammed Jabbar Hatemi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ischemic Disorders Research Center, International Campus, Golestan University of Medical Sciences, Gorgan, Iran. Hauptthemen laut MEDLINE: Dexmedetomidine, Hemodynamics, Cardiac Surgical Procedures, Interleukin-13. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have explored the anti-inflammatory effects of drugs in cardiac surgery. Dexmedetomidine (Dex), a centrally acting alpha-agonist, is believed to possess anti-inflammatory properties. We conducted a randomized, double-blind, controlled trial to assess the anti-inflammatory effects of Dex in patients undergoing open-heart surgery with cardiopulmonary bypass.

Methods

Adult eligible patients undergoing cardiac surgery with cardiopulmonary bypass were randomly assigned to receive either standard anesthetics or De × 0.5 μg/kg/h in addition to anesthetics in a single-center, randomized, double-blinded study. The primary outcome was the change in inflammatory mediators (∆) in plasma 24 hours postsurgery compared with baseline, measured by ELISA. Secondary outcomes are defined as changes in hemodynamic and biological markers, recovery time, and Dex’s safety.

Results

In total, 80 patients were included in the control and Dex groups. The Dex group increased IL-13 levels as anti-inflammatory cytokines, while it was decreased in the control group. Dex reduced the levels of interleukin (IL)-6 ( P = 0.777) and IL-18 ( P = 0.895) at the 24 hours postsurgery, with no statically significant difference against the control group. Both groups did not increase the levels of IL-1β and TNF-α regards to baseline ( P = 0.812 and P = 0.420, respectively); however, this increase was lower in the Dex group for TNF-α and slightly higher for IL-1β. Dex provided better hemodynamic and repository stability. In addition, the incidence of common events including hypotension, bradycardia, and tachycardia was higher in the control group than in Dex.

Conclusion

We found that administering Dex at the onset of anesthesia and during cardiopulmonary bypass reduces inflammatory factors, promotes hemodynamic stability, and enhances patient safety. It may offer significant benefits for those undergoing open heart surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineHemodynamicsCardiac Surgical ProceduresInterleukin-13InflammationAnti-Inflammatory AgentsHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedCardiopulmonary BypassAdult

Stichwörter der Autor:innen

DexmedetomidineIL-13hemodynamic stabilityinflammatoryoff-pumpopen-heart surgery

Substanzen

DexmedetomidineInterleukin-13Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Ischemic Disorders Research Center, International Campus, Golestan University of Medical Sciences, Gorgan, Iran.
  • Anesthesia Techniques Department, College of Health and Medical Techniques, Al-Mustaqbal University, Babylon, Hillah, Iraq.
  • Ischemic Disorders Research Center, Jorjani Clinical Sciences Research Institute, Golestan.
  • Cancer Research Center, Golestan University of Medical Sciences, Gorgan.
  • Department of Anesthesiology and Critical Care Medicine, Golestan University of Medical Sciences, Gorgan.
  • Department of Anesthesiology, School of Medicine faculty, Tehran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Hatemi, B. M. J., Enayati, A., Ghorbani, S., Tahmasebi, F., Aljadayel, H. A., Jabbari, A., & Movafegh, A. (2025). Dexmedetomidine Improves Inflammatory Stress and Hemodynamic in Patients Undergoing Open Heart Surgery via Interleukin-13: A Randomized, Double-Blind, Controlled, Clinical Trial. Annals of Cardiac Anaesthesia. https://doi.org/10.4103/aca.aca_5_25

Vancouver

Hatemi BMJ, Enayati A, Ghorbani S, Tahmasebi F, Aljadayel HA, Jabbari A, et al. Dexmedetomidine Improves Inflammatory Stress and Hemodynamic in Patients Undergoing Open Heart Surgery via Interleukin-13: A Randomized, Double-Blind, Controlled, Clinical Trial. Annals of Cardiac Anaesthesia. 2025. doi:10.4103/aca.aca_5_25

BibTeX
@article{Hatemi2025,
  author = {Hatemi, Bassim Mohammed Jabbar and Enayati, Ayesheh and Ghorbani, Somayeh and Tahmasebi, Fatemeh and Aljadayel, Hadi Abo and Jabbari, Ali and Movafegh, Ali},
  title = {Dexmedetomidine Improves Inflammatory Stress and Hemodynamic in Patients Undergoing Open Heart Surgery via Interleukin-13: A Randomized, Double-Blind, Controlled, Clinical Trial},
  journal = {Annals of Cardiac Anaesthesia},
  year = {2025},
  doi = {10.4103/aca.aca_5_25}
}
Kostenlos starten →